Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Heavy Ion Research Institute

3 abstracts

Abstract
Phase Ib study of neoadjuvant concurrent chemoradiation plus durvalumab followed by surgery and adjuvant durvalumab for resectable stage III NSCLC.
Org: Lung Cancer Center, Yonsei Cancer Center, Yonsei University Health System, Yonsei University College of Medicine, Heavy Ion Research Institute, Department of Thoracic and Cardiovascular Surgery,
Abstract
Dynamic change of immune phenotype assessed by artificial intelligence (AI)-powered analysis of tumor-infiltrating lymphocytes (TILs) during neoadjuvant durvalumab with or without tremelimumab (D+/-T) in head and neck squamous cell carcinoma (HNSCC).
Org: Yonsei Cancer Center, Yonsei University Health System, Lunit Inc., Heavy Ion Research Institute,
Abstract
Neoadjuvant pembrolizumab, GX-188E, and GX-I7 in patients with human papillomavirus-16- and/or 18-positive head and neck squamous cell carcinoma: Single-arm, phase 2 trial with single cell transcriptomic analysis and artificial intelligence-powered spatial analysis.
Org: Genome Insight Inc., Heavy Ion Research Institute, Korea Advanced Institute of Science and Technology, Lunit Inc.,